2023
High-throughput functional analysis of autism genes in zebrafish identifies convergence in dopaminergic and neuroimmune pathways
Mendes H, Neelakantan U, Liu Y, Fitzpatrick S, Chen T, Wu W, Pruitt A, Jin D, Jamadagni P, Carlson M, Lacadie C, Enriquez K, Li N, Zhao D, Ijaz S, Sakai C, Szi C, Rooney B, Ghosh M, Nwabudike I, Gorodezky A, Chowdhury S, Zaheer M, McLaughlin S, Fernandez J, Wu J, Eilbott J, Vander Wyk B, Rihel J, Papademetris X, Wang Z, Hoffman E. High-throughput functional analysis of autism genes in zebrafish identifies convergence in dopaminergic and neuroimmune pathways. Cell Reports 2023, 42: 112243. PMID: 36933215, PMCID: PMC10277173, DOI: 10.1016/j.celrep.2023.112243.Peer-Reviewed Original ResearchConceptsGene lossFunctional analysisHigh-throughput functional analysisZebrafish mutantsGene discoverySelect mutantsASD genesAutism genesKey pathwaysASD biologyBrain size differencesMutantsGenesSize differencesPathwayGlobal increaseRelevant mechanismsBiologyCentral challengeNeuroimmune dysfunctionRegionFunctionDiscoveryAutism spectrum disorder
2017
Challenges in Conducting Clinical Trials for Pharmacotherapies in Fragile X Syndrome: Lessons Learned
Harkins C, Dominick K, Wink L, Pedapati E, Shaffer R, Fitzpatrick S, Davenport M, Sweeney J, Erickson C. Challenges in Conducting Clinical Trials for Pharmacotherapies in Fragile X Syndrome: Lessons Learned. Pharmaceutical Medicine 2017, 31: 235-244. DOI: 10.1007/s40290-017-0199-1.Peer-Reviewed Original ResearchAutism spectrum disorderFragile X syndromeBehavioral outcome measuresClinician-reported instrumentsUse of parentsBehavioral measuresEye gazeSpectrum disorderNeuroscientific advancesReport instrumentX syndromeTreatment developmentCommon single gene causeBrain functionRater biasBehavioral heterogeneityIntellectual disabilityPharmacotherapy trialsOutcome measuresPotential explanationTreatment-associated changesQuantitative measuresMeasuresDisordersFuture success
2016
A Randomized, Double-Blind, Placebo-Controlled Trial of Low-Dose Sertraline in Young Children With Fragile X Syndrome
Greiss Hess L, Fitzpatrick S, Nguyen D, Chen Y, Gaul K, Schneider A, Lemons Chitwood K, Eldeeb M, Polussa J, Hessl D, Rivera S, Hagerman R. A Randomized, Double-Blind, Placebo-Controlled Trial of Low-Dose Sertraline in Young Children With Fragile X Syndrome. Journal Of Developmental And Behavioral Pediatrics 2016, 37: 619-628. PMID: 27560971, PMCID: PMC5039060, DOI: 10.1097/dbp.0000000000000334.Peer-Reviewed Original ResearchConceptsLow-dose sertralineEL developmentFragile X syndromeYoung childrenSensory Processing Measure–PreschoolVisual perceptual abilitiesAutism spectrum disorderSocial participationLong-term side effectsPerceptual abilitiesMullen ScalesLanguage developmentSpectrum disorderX syndromeAge equivalentsSide effectsSertraline armClinical Global Impression Scale-ImprovementMSELEarly childhoodSelective serotonin reuptake inhibitorsGlobal clinical improvementChildrenPlacebo-controlled trialSerious adverse eventsAggression in autism spectrum disorder: presentation and treatment options
Fitzpatrick S, Srivorakiat L, Wink L, Pedapati E, Erickson C. Aggression in autism spectrum disorder: presentation and treatment options. Neuropsychiatric Disease And Treatment 2016, Volume 12: 1525-1538. PMID: 27382295, PMCID: PMC4922773, DOI: 10.2147/ndt.s84585.Peer-Reviewed Original ResearchAutism spectrum disorderSpectrum disorderFunctional communication trainingASD diagnosisFunctional behavioral assessmentSocial communicationNegative outcomesSocial interactionSocial supportDevelopmental disabilitiesPersistent difficultiesBehavioral assessmentCommunication trainingAggressionNeurodevelopmental disordersAggressive behaviorRepetitive patternsDisordersReinforcement strategiesIndividualsStress levelsQuality of lifeAggression ratesCaregiversSecond-generation antipsychotics